Citizens JMP lowered the firm’s price target on Jasper Therapeutics (JSPR) to $6 from $12 and keeps an Outperform rating on the shares. Jasper Therapeutics announced early findings from its investigation into the confounding results from two cohorts in the BEACON study, and the issue now points to sites or enrolled patients, the analyst says. Jasper also announced the pricing of a $30M public offering, which will extend its runway past updated CSU data coming at year-end 2025 and into the third quarter of 2026. The bridge financing deal removes a key overhang for Jasper, Citizens says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics Announces $30 Million Public Offering
- Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43
- Jasper Therapeutics announces common stock offering, no amount given
- Jasper Therapeutics price target lowered to $25 from $29 at UBS
- Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline